Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Companies in #Epidermolysis bullosa

Found 1 company operating in this sector.

Commercial-stage cell and gene therapy company. Its ZEVASKYN (prademagene zamikeracel) autologous cell sheet was approved by the FDA in April 2025 for recessive dystrophic epidermolysis bullosa, and FAYUVI (ABO-102) became the company's second approved gene therapy in 2026 for mucopolysaccharidosis type IIIA. Abeona added APT-1011 (ABO-801), a Phase 3-ready orally disintegrating fluticasone formulation for eosinophilic esophagitis, in November 2026 and is advancing its SIR-T synthetic immune receptor platform, led by PSMA-targeted ABO-701 for advanced prostate cancer.

Sector:Cell & Gene Therapy
HQ:Cleveland, OH, USA